SIRT3 and familial pancreatic carcinoma: Tris DBA’s capacity to modulate autophagy and reduce mitochondrial ROS highlights the potential ability of targeting SIRT3 to reverse the metabolic dysregulation commonly observed in pancreatic cancer.